BioSight
Companies
MANNKIND CORP logo

MNKD

NASDAQDANBURY, CT
MANNKIND CORP

MannKind Corporation commercializes inhaled insulin Afrezza for diabetes, along with intravenous furosemide Furoscix and subcutaneous infusion device V-Go, representing a combination of commercial-stage products utilizing its proprietary Technosphere drug delivery platform across endocrinology and acute care settings. The company is advancing MNKD-201 in clinical development and planning pediatric expansion of Afrezza and a new Furoscix ReadyFlow Autoinjector formulation for 2026.

Price history not yet available for MNKD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar